

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1-8. Canceled.

9. (Currently amended) A ~~use of an inhibitor of soluble epoxide hydrolase ("sEH") for the manufacture of a medicament to inhibit or slow progression method of inhibiting progression in a patient of~~ condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, ~~comprising administering to said patient an effective amount of an inhibitor of soluble epoxide hydrolase ("sEH").~~

10. (Currently amended) A ~~use method~~ of claim 9, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

11. (Currently amended) A ~~use method~~ of claim 9, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

12. (Currently amended) A ~~use method~~ of claim 9, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

13. (Currently amended) A ~~use method~~ of claim 9, wherein the condition is asthma.

14. (Currently amended) A ~~use method~~ of claim 9, wherein said inhibitor of sEH is selected from the group consisting of an adamantly dodecyl urea, N-cyclohexyl-N'-dodecyl urea (CDU) and N, N'-dicyclohexylurea (DCU).

15. (Currently amended) A ~~use method~~ of claim 9, wherein the ~~medicament is inhibitor is in~~ a slow release formulation.

16. (Currently amended) A use method of claim 9, ~~wherein said medicament further comprises further comprising administering a cis-epoxyeicosantrienoic acid ("EET").~~

17. (Currently amended) A use method of claim 9, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

18. (Currently amended) A use method of claim 9, wherein said EET is 14R,15S-EE T.

19. (Currently amended) A use of a nucleic acid that inhibits expression of soluble epoxide hydrolase ("sEH") for the manufacture of a medicament for inhibiting or slowing progression-method of inhibiting progression in a patient of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, comprising administering to said patient an effective amount of a nucleic acid that inhibits expression of soluble epoxide hydrolase ("sEH").

20. (Currently amended) A use method of claim 19, wherein the nucleic acid is a small interfering RNA.

21. (Currently amended) A use method of claim 19, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

22. (Currently amended) A use method of claim 19, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

23. (Currently amended) A use method of claim 19, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

24. (Currently amended) A use method of claim 19, wherein the condition is asthma.

25. (Withdrawn) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and asthma, said method comprising administering an inhibitor of soluble epoxide hydrolase ("sEH") and a *cis*-epoxyeicosantrienoic acid ("EET") to a person in need thereof.

26. (Withdrawn) A method of claim 25, wherein said obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

27. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

28. (Withdrawn) A method of claim 25, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

29. (Withdrawn) A method of claim 25, wherein the condition is asthma.

30. (Withdrawn) A method of claim 25, wherein the inhibitor of sEH or the EET, or both, is in a material which releases the inhibitor over time.

31. (Withdrawn) A method of claim 25, wherein said EET is selected from the group consisting of 14,15-EET, 8,9-EET and 11,12-EET.

32. (Withdrawn) A method of claim 25, wherein said EET is 14R,15S-EET.

33. (Withdrawn) A method of claim 25, wherein the inhibitor is administered orally.

34. (Withdrawn) A method of claim 25, wherein the inhibitor is administered in a total daily dose from about 0.001 mg/kg to about 100 mg/kg body weight.

35. (Withdrawn) A method of inhibiting progression of a condition selected from the group consisting of an obstructive pulmonary disease, an interstitial lung disease, and

asthma, said method comprising administering to a person in need thereof a nucleic acid which inhibits expression of a gene encoding soluble epoxide hydrolase ("sEH"), and a *cis*-epoxyeicosantrienoic acid ("EET").

36. (Withdrawn) A method of claim 35, wherein the obstructive pulmonary disease is selected from the group consisting of chronic obstructive pulmonary disease ("COPD"), emphysema, and chronic bronchitis.

37. (Withdrawn) A method of claim 35, wherein the interstitial lung disease is idiopathic pulmonary fibrosis.

38. (Withdrawn) A method of claim 35, wherein the interstitial lung disease is one associated with occupational exposure to a dust.

39. (Withdrawn) A method of claim 35, wherein the condition is asthma.

40. (Withdrawn) A method of claim 35, wherein the nucleic acid is a small interfering RNA ("siRNA").